Biocon is shifting its strategy to focus on capacity utilization, margin expansion, and improved returns after significant investments in g...

Biocon's fourth-quarter net profit saw a significant drop of 63 percent year-on-year. This decline was attributed to exceptional charges im...

Smallcap and midcap stocks outperformed benchmarks on Friday, with select names rallying up to 16% despite broader market weakness. Gains w...

Biocon Ltd reported a 56.8% drop in Q4 net profit to Rs 198.6 crore, impacted by an Rs 80.4 crore exceptional item. Despite this, consolida...

Indian markets showed resilience, climbing despite volatility, buoyed by positive global trends and falling crude oil prices. Analysts anti...

Smallcap and midcap stocks surged on Wednesday, outperforming broader market indices with gains of around 1% each. This rally was fueled by...

Markets closed lower amid global headwinds and geopolitical worries. Several companies like Paytm, Bajaj Auto, and L&T are in focus due to ...

Biocon founder Kiran Mazumdar-Shaw has announced her successor. Niece Claire Mazumdar will lead the company. Claire Mazumdar is the founder...

Biocon founder Kiran Mazumdar-Shaw has named her niece, Claire Mazumdar, as her successor. Claire Mazumdar, a successful CEO of Bicara Ther...

Syngene shares surged despite a 19% YoY decline in Q4FY26 net profit to Rs 148 crore, as earnings rebounded sharply from Rs 15 crore in the...

US company’s board meeting is happening this weekend to finalise decision; an announcement is imminent later tonight or by Monday. Mumbai H...

Markets surged for the fourth consecutive session, buoyed by favorable geopolitical cues. Key stocks like TCS, HDFC Bank, ITC Hotels, Hyund...

Biocon Group reported a strong Q2 FY26 with a 20% year-on-year increase in operating revenue to Rs 4,296 crore, driven by biosimilars and g...

Biocon's Q1 net profit declined 95% year-on-year, but on a like-for-like basis, profit after tax increased by 65%. Revenue grew 15% to Rs 3...

Biocon share price: Biocon reported a 96% year-on-year (YoY) decline in net profit, which fell to Rs 25 crore in Q3FY25. In comparison, the...

For the financial year 2019-20, the biopharma company posted a 15% growth in revenue at Rs 6,529 crore.

her focus area for the company will be out-licensing and global development of novel molecules, Biocon said in an investor presentation.